-
Product Insights
NewCaspase 2 – Drugs In Development, 2024
The Caspase 2 pipeline drugs market research report outlays comprehensive information on the Caspase 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Ophthalmology, Central Nervous System, Gastrointestinal, and Immunology which include indications of Open-Angle Glaucoma, Non-Arteritic Anterior Ischemic Optic Neuropathy, Unspecified Central Nervous System Disorders, Hypoxic-Ischemic Encephalopathy, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, and Inflammation. It...
-
Product Insights
NewLow Density Lipoprotein Receptor Related Protein – Drugs In Development, 2024
The Low Density Lipoprotein Receptor Related Protein pipeline drugs market research report outlays comprehensive information on the Low Density Lipoprotein Receptor Related Protein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Ophthalmology, Central Nervous System, Musculoskeletal Disorders, and Respiratory which include indications of Optic Nerve Injury, Diabetic Retinopathy, Alzheimer's Disease, Multiple Sclerosis, Osteoporosis, Osteonecrosis, Idiopathic Pulmonary Fibrosis,...
-
Product Insights
NewProlow Density Lipoprotein Receptor Related Protein 1 – Drugs In Development, 2024
The Prolow Density Lipoprotein Receptor Related Protein 1 pipeline drugs market research report outlays comprehensive information on the Prolow Density Lipoprotein Receptor Related Protein 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Ophthalmology, Immunology, and Metabolic Disorders which include indications of Alzheimer's Disease, Multiple Sclerosis, Optic Nerve Injury, Glaucoma, Autoimmune Disorders, Pemphigus Vulgaris,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IM-101 in Autoimmune Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IM-101 in Autoimmune Disorders report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IM-101 in Autoimmune Disorders Drug Details: IM-101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IM-101 in Age Related Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IM-101 in Age Related Macular Degeneration report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IM-101 in Age Related Macular Degeneration Drug Details: IM-101...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IM-101 in Myasthenia Gravis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IM-101 in Myasthenia Gravis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IM-101 in Myasthenia Gravis Drug Details: IM-101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IM-101 in Paroxysmal Nocturnal Hemoglobinuria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IM-101 in Paroxysmal Nocturnal Hemoglobinuria report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IM-101 in Paroxysmal Nocturnal Hemoglobinuria Drug Details: IM-101 is under...
-
Company Insights
NewHypervision Surgical Ltd Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our Hypervision Surgical Ltd Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. Hypervision Surgical Ltd (Hypervision Surgical) is a provider of optical imaging modality solutions in medical devices. The company specializes in providing computer-assisted tissue analysis for medical surgeries to minimise patient risk and neurological impairment. It uses safe optical imaging, quantitative AI imaging, tissue differentiation models for improved surgical precision and patient safety. The company’s quantitative AI imaging technology provides...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MyMD-1 in Sarcopenia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MyMD-1 in Sarcopenia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MyMD-1 in Sarcopenia Drug Details: MyMD-1 (Isomyosamine) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atacicept in IgA Nephropathy (Berger’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atacicept in IgA Nephropathy (Berger's Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atacicept in IgA Nephropathy (Berger's Disease) Drug Details: Atacicept...